Given that patients with elevated Lp(a) remain at residual risk of ASCVD (Bittner et al., 2020), the mechanisms whereby PCSK9 inhibitors lower Lp(a) concentrations merit investigation. Here, PCSK9 is linked to atherosclerosis.